Fast-Dissolving Films of Sumatriptan Succinate: Factorial Design to Optimize In Vitro Dispersion Time
Tóm tắt
Sumatriptan succinate, a serotonin 5-HT agonist, commonly used for migraine has erratic absorption from the gastrointestinal tract following oral administration and undergoes first-pass metabolism, resulting in a low bioavailability. The present study was undertaken to formulate fast-dissolving films of sumatriptan succinate meant to be quickly dispersed in the mouth. Films were prepared by solvent casting method and characterized for thickness, folding endurance, elongation, surface pH, and content uniformity. A 32 factorial design was used to optimize the in vitro dispersion time of films, and in vitro dissolution study was studied to determine the drug release. Ex vivo buccal permeation study was carried out using goat buccal mucosa mounted on a modified Franz diffusion cell. The optimized in vitro dispersion time for both the type of films was ∼30 s. The in vitro drug dissolution was complete in 90 s for both types of films. Thirty-eight percent of the drug was permeated from the hydroxy propyl methyl cellulose (HPMC) film, and about 42 % was permeated from maltodextrin film in 30 min. Such fast-dissolving films of sumatriptan succinate would mediate the release of drug and would be potentially useful for the treatment of migraine where quick onset of action is required.
Tài liệu tham khảo
Pakalnis A, Kring D, Paolicchi J. Parenteral satisfaction with sumatriptan nasal spray in childhood migraine. J Child Neurol. 2003;18:772–5.
Villalon CM, Centurion D, Valdivia LF, de Vries P, Saxena PR. Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003;1:71–84.
Ahonen K, Hamalainen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology. 2004;62:883–7.
Fuseau E, Petricoul O, Moore KH, Barrow A, Ibbotson T. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet. 2002;41:801–11.
Pierce MW. Transdermal delivery of sumatriptan for the treatment of acute migraine. Neurotherapeutics. 2010;7:159–63.
Jain SA, Chauk DS, Mahajan HS, Tekade AR, Gattani SG. Formulation and evaluation of nasal mucoadhesive microspheres of sumatriptan succinate. J Microencapsul. 2009;26(8):711–21.
Shivanand K, Raju SA, Nizamuddin S, Jayakar B. In vivo bioavailability studies of sumatriptan succinate buccal tablets. DARU J. 2011;19(3):224.
Gugulothu D, Desai P, Pandharipande P, Patravale V. Freeze drying: exploring potential in development of orodispersible tablets of sumatriptan succinate. Drug Dev Ind Pharm. 2014. doi:10.3109/03639045.2013.871551.
Kundu J, Patra C, Kundu SC. Design, fabrication and characterization of silk fibroin-HPMC-PEG blended films as vehicle for transmucosal delivery. Mater Sci Eng C. 2008;28:1376–80.
Dinge A, Nagarsenker M. Formulation and evaluation of fast dissolving films for delivery of triclosan to the oral cavity. AAPS PharmSciTech. 2008;9:349–56.
Cilurzo F, Cupone IE, Minghetti P, Selmin F, Montanari L. Fast dissolving films made of maltodextrins. Eur J Pharm Biopharm. 2008;70(3):895–900.
Bryson NJ, Giovinazzo AJ, Barnhart SD, Koons MC. Sublingual films. U.S. Patent 8,414,922, issued April 9, 2013. Washington, DC: U.S. Patent and Trademark Office; 2013.
Mehta AK, Yadav KS, Sawant KK. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation. Curr Drug Deliv. 2007;4(3):185–93.
Cilurzo F, Cupone IE, Minghetti P, Buratti S, Selmin F, Gennari CG, et al. Nicotine fast dissolving films made of maltodextrins: a feasibility study. AAPS PharmSciTech. 2010;11:1511–7.
Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release. 2009;139(2):94–10.
Mashru RC, Sutariya VVB, Snkalia MMG, Parikh PP. Development and evaluation of fast-dissolving film of salbutamol sulphate. Drug Dev Ind Pharm. 2005;31:25–34.
Singh H, Kaur M, Verma H. Optimization and evaluation of desloratadine oral strip: an innovation in paediatric medication. Sci World J. 2013;2013:395681.
Yadav KS, Sawant KK. Formulation optimization of etoposide loaded PLGA nanoparticles by double factorial design and their evaluation. Curr Drug Deliv. 2010;7(1):51–64.
Soni G, Yadav KS. High encapsulation efficiency of poloxamer-based injectable thermoresponsive hydrogels of etoposide. Pharm Dev Technol. 2014;19:651–61.
Yadav KS, Sawant KK. Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles. AAPS PharmSciTech. 2010;11(3):1456–65.
Yadav KS, Jacob S, Sachdeva G, Chuttani K, Mishra AK, Sawant KK. Long circulating PEGylated PLGA nanoparticles of cytarabine for targeting leukemia. J Microencapsul. 2011;28(8):729–42.
El-Setouhy D, El-Malak NSA. Formulation of a novel tinapetine sodium orodispersible film. AAPS PharmSciTech. 2010;11:1018–25.
Parejiya PB, Patel RC, Mehta DM, Shelat PK, Barot BS. Quick dissolving films of nebivolol hydrochloride: formulation and optimization by a simplex lattice design. J Pharm Investig. 2013;43:343–51.
Patel VM, Prajapati BG, Patel MM. Effect of hydrophilic polymers on buccoadhesive Eudragit patches of propranolol hydrochloride using factorial design. AAPS PharmSciTech. 2007;8(2):E119–26.
Myers GL, Fuisz RC. Film compositions for delivery of actives. U.S. Patent Application 12/779,316, filed May 13. 2010.
Low AQJ, Parmentier J, Khong YM, Chai CCE, Tun TY, Berania JE, et al. Effect of type and ratio of solubilising polymer on characteristics of hot-melt extruded orodispersible films. Int J Pharm. 2013;455:138–47.
Galey WR, Lonsdale HK, Nacht S. The in vitro permeability of skin and buccal mucosa to selected drugs and tritiated water. J Investig Dermatol. 1976;67:713–7.
Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci. 1998;1(1):15–30.